Drug Trial Radar · NCT05070858
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
288
Actual
Start
Dec 14, 2021
Primary completion
Jul 8, 2025
Study completion Nov 11, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How the study drugs work inside the body * How much of the study drugs are in the blood at different times * Whether the body makes antibodies against pozelimab and cemdisiran (which could make the drugs less effective or could lead to side effects)
Conditions
- Generalized Myasthenia Gravis
Interventions
Pozelimab + CemdisiranDrug
Subcutaneous administration as described in the protocol
CemdisiranDrug
SC administration as described in the protocol
PlaceboOther
SC administration as described in the protocol
PozelimabDrug
SC administration as described in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total scoreTime frame: From baseline to week 24
Locations
116 sites in 19 countries. Site status is shown where the registry gives one.
HonorHealth Neurology 2018
Scottsdale, Arizona
University of California Irvine
Irvine, California
University of Southern California
Los Angeles, California
Colorado Springs Neurological Associates
Colorado Springs, Colorado
SFM Clinical Research, LLC
Boca Raton, Florida
Diverse Clinical Research
Miami, Florida
Aqualane Clinical Research
Naples, Florida
Neurological Services of Orlando
Orlando, Florida
Medsol Clinical Research Center Inc
Port Charlotte, Florida
University of South Florida Morsani Center for Advanced Healthcare
Tampa, Florida
NorthShore University Health System
Glenview, Illinois
St. Elizabeth's Hospital
O'Fallon, Illinois
Northwest Neurology Ltd. - Clinedge - PPDS
Rolling Meadows, Illinois
Wayne State University School of Medicine
Detroit, Michigan
Dayton Center for Neurological Disorders
Centerville, Ohio
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio
Penn Medicine University City
Philadelphia, Pennsylvania
National Neuromuscular Research Institute
Austin, Texas
Nerve and Muscle Center of Texas
Houston, Texas
Universitair Ziekenhuis Antwerpen
Edegem, Antwerp, Belgium
AZ Sint-Lucas
Ghent, Oost-Vlaanderen, Belgium
Pseg Centro de Pesquisa Clinica S.A
São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, Brazil
IMV Pesquisa Neurologica
Porto Alegre, Rio Grande do Sul, Brazil
Jordy Sinapse Medicina LTDA
Itapevi, São Paulo, Brazil
Faculdade de Medicina Do ABC
Santo André, São Paulo, Brazil
University of Alberta
Edmonton, Alberta, Canada
London Health Sciences Centre
London, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Guangdong Hospital of Traditional Chinese Medicine
Guangdong, Guangdong, China
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangzhou, China
Hainan General Hospital
Haikou, Hainan, China
Renmin Hospital of Wuhan University - Hubei Provincial People's Hospital
Wuhan, Hubei, China
Xiangya Hospital Central South University
Changsha, Hunan, China
The First Hospital of Jilin University
Changchun, Jilin, China
Qilu Hospital of Shandong University (Qingdan)
Qingdao, Shandong, China
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.